Termination of Information and Inspection Rights. The covenants set forth in Sections 2.1 and 2.2 shall terminate as to each Major Holder and be of no further force or effect when the sale of securities pursuant to a registration statement filed by the Company under the Act in connection with the firm commitment underwritten offering of its securities to the general public is consummated or when the Company first becomes subject to the periodic reporting requirements of Sections 12(g) or 15(d) of the 1934 Act, whichever event shall occur first.
Appears in 2 contracts
Samples: License Agreement (Orexigen Therapeutics, Inc.), License Agreement (Orexigen Therapeutics, Inc.)
Termination of Information and Inspection Rights. The covenants set forth in Sections 2.1 Section 3.2 and 2.2 Section 3.3 shall terminate as to each Major Holder the Investors and be of no further force or effect when (i) immediately upon the consummation of the Company's sale of securities pursuant to its Common Stock in a registration statement filed by the Company under the Act in connection with the firm commitment underwritten offering of its securities to the general public is consummated Qualified Offering or (ii) when the Company first becomes subject is required to the periodic reporting requirements of Sections file reports pursuant to Section 12(g) or 15(d) of the 1934 Act, whichever event shall occur first.
Appears in 1 contract
Samples: Rights Agreement (Techwell Inc)
Termination of Information and Inspection Rights. The covenants set forth in Sections 2.1 and 2.2 shall terminate as to each Major Holder and be of no further force or effect when upon the sale of securities pursuant to a registration statement filed by the Company under the Act in connection with the firm commitment underwritten offering of its securities to the general public is consummated IPO or when the Company first becomes subject to the periodic reporting requirements of Sections 12(g) or 15(d) of the 1934 Act, whichever event shall occur first.
Appears in 1 contract
Samples: Investors’ Rights Agreement (Orexigen Therapeutics, Inc.)